Bemfola is a recombinant follicle-stimulating hormone (FSH) used during infertility treatment. One main differentiator between FSH products is their delivery device; consisting of multi-dose pens (Gonal-f), vials or multi-dose preparations (Menopur), or adjustable daily disposable dose pens (Bemfola). To determine the potential impact of delivery device on drug wastage during infertility treatment this study retrospectively analysed Gonal-f and Menopur prescription and usage data from five UK clinics. Incurred drug wastage was then compared to potential Bemfola drug wastage. Data collected included: (i) number of treatment cycles; (ii) daily FSH dose; (iii) length of treatment; (iv) dose adjustment following ultrasound scan; (v) FSH formulation(s) prescribed and (vi) agonist/antagonist protocol used. Treatment with Gonal-f (4078 cycles) and Menopur (646 cycles) resulted in an average drug wastage of 160 and 294 IU per treatment cycle. Use of Bemfola instead of Gonal-f and Menopur may reduce the wastage to 104 and 61 IU per cycle, respectively. The use of Bemfola, across all 4724 cycles, could result in a drug wastage reduction of up to 376,800 IUs with an associated cost saving of £100,011. Bemfola is a viable alternative to Gonal-f and Menopur with its drug delivery system potentially reducing drug wastage and associated costs during infertility treatment.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1080/14647273.2017.1328131 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Integrating natural product research laboratory with artificial intelligence: Advancements and breakthroughs in traditional medicine.
Biomedicine (Taipei)
December 2024
Million-Person Precision Medicine Initiative, Department of Medical Research, China Medical University Hospital, Taichung, Taiwan.
The Natural Product Research Laboratory (NPRL) of China Medical University Hospital (CMUH) was established in collaboration with CMUH and Professor Kuo-Hsiung Lee from the University of North Carolina at Chapel Hill. The laboratory collection features over 6000 natural products worldwide, including pure compounds and semi-synthetic derivatives. This is the most comprehensive and fully operational natural product database in Taiwan.
View Article and Find Full Text PDFIntegrating melt electrospinning writing and microfluidics to engineer a human cardiac microenvironment for high-fidelity drug screening.
Bioact Mater
March 2025
Academy of Medical Engineering and Translational Medicine, Tianjin University, 300072, China.
The preclinical evaluation of drug-induced cardiotoxicity is critical for developing novel drug, helping to avoid drug wastage and post-marketing withdrawal. Although human induced pluripotent stem cell-derived cardiomyocytes (iPSC-CMs) and the engineered heart organoid have been used for drug screening and mimicking disease models, they are always limited by the immaturity and lack of functionality of the cardiomyocytes. In this study, we constructed a Cardiomyocytes-on-a-Chip (CoC) that combines micro-grooves (MGs) and circulating mechanical stimulation to recapitulate the well-organized structure and stable beating of myocardial tissue.
View Article and Find Full Text PDFHow do patients determine when their inhaler is empty? Insights from an analysis of returned inhalers and a patient survey.
BMJ Open Respir Res
December 2024
Chiesi Ltd, Manchester, UK
Background: Inhalers are widely used for the management of asthma and chronic obstructive pulmonary disease. However, there is little knowledge about the extent to which an inhaler is used and when it is disposed of, despite the implications for an individual's health (when used beyond the recommended number of doses (overused)), and medicine wastage, healthcare costs and the environment (when discarded with remaining doses (underused)). To explore inhaler use, we assessed the number of doses remaining in pressurised metered-dose inhalers (pMDIs) returned via a Chiesi Inhaler Recycling scheme.
View Article and Find Full Text PDFCost-Effective and Sustainable Drug Use in Hospitals: A Systematic and Practice-Based Approach.
Appl Health Econ Health Policy
December 2024
Department of Market Strategy and Healthcare Financing, Erasmus University Medical Center, Rotterdam, The Netherlands.
Background And Objective: Rising healthcare costs challenge the financial sustainability of healthcare systems. Interventional pharmacoeconomics has emerged as a vital discipline to improve the cost-effective and sustainable use of drugs in clinical practice. However, current efforts are often fragmented, highlighting the need for an integrated hospital-wide approach.
View Article and Find Full Text PDFRecent advances in microfluidic chip technologies for applications as preclinical testing devices for the diagnosis and treatment of triple-negative breast cancers.
Pathol Res Pract
December 2024
Iqraa Centre for Research and Development, IQRAA International Hospital and Research Centre, Kozhikode, Kerala, India.
The leading cause of cancer-related death among female patients is breast cancer. Among all the types of breast cancer, triple-negative breast cancer (TNBC) is the most dangerous molecular subtype of breast cancer characterized by the absence of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER-2) expression. Since there is no particular therapeutic strategy for TNBC that has been shown to worsen the disease prognosis, 3D models are superior to 2D models as a predictive tool for drug discovery because they more accurately reflect the in vivo biological components of humans.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!